.Nature Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of clients along with HER2+ state-of-the-art bosom cancer cells and also active or even secure human brain metastases presented constant intracranial task as well as systemic efficiency of T-DXd.